Inflammatory articular disease in patients with inflammatory bowel disease: Result of the Swiss IBD cohort study

Inflammatory Bowel Diseases

Volumn 21, Issue 11, 2015, Pages 2598-2604

  Ditisheim, Saskia ^a   Fournier, Nicolas ^b   Juillerat, Pascal ^c   Pittet, Valerie ^b   Michetti, Pierre ^d   Gabay, Cem ^a   Finckh, Axel ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Crohn's disease; inflammatory arthritides; inflammatory bowel disease; spondyloarthropathy; Swiss IBD cohort study; ulcerative colitis

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; APHTHOUS STOMATITIS; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; ARTICLE; BODY MASS; CLINICAL EVALUATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENTEROPATHY; ERYTHEMA NODOSUM; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFLAMMATION; INFLAMMATORY ARTICULAR DISEASE; INFLAMMATORY BOWEL DISEASE; IRITIS; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL SYSTEM INFLAMMATION; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RECURRENT DISEASE; RISK FACTOR; SENESCENCE; SEX RATIO; SMOKING; ULCERATIVE COLITIS; UVEITIS; CLINICAL TRIAL; COLITIS, ULCERATIVE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; SWITZERLAND; TOBACCO USE;

ADULT; ARTHRALGIA; ARTHRITIS; BODY MASS INDEX; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SWITZERLAND; TOBACCO USE;

EID: 84945244266     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000548     Document Type: Article

References (47)

1. Rodriguez-Reyna TS, Martinez-Reyes C, Yamamoto-Furusho JK. Rheumatic manifestations of inflammatory bowel disease. World J Gastroenterol. 2009;15:5517-5524.
2. Reveille JD. Genetics of spondyloarthritis-beyond the MHC. Nat Rev Rheumatol. 2012;8:296-304.
3. Laukens D, Georges M, Libioulle C, et al. Evidence for significant overlap between common risk variants for Crohn's disease and ankylosing spondylitis. PLoS One. 2010;5:e13795.
4. Brakenhoff LK, van der Heijde DM, Hommes DW. IBD and arthropathies: a practical approach to its diagnosis and management. Gut. 2011;60: 1426-1435.
5. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387-391.
6. Salvarani C, Vlachonikolis IG, van der Heijde DM, et al. Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol. 2001;36:1307-1313.
7. Turkcapar N, Toruner M, Soykan I, et al. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int. 2006;26:663-668.
8. Palm O, Moum B, Ongre A, et al. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol. 2002;29:511-515.
9. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23:29-34.
10. Palm O, Moum B, Jahnsen J, et al. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford). 2001;40:1256-1261.
11. Peeters M, Ghoos Y, Maes B, et al. Increased permeability of macroscopically normal small bowel in Crohn's disease. Dig Dis Sci. 1994; 39:2170-2176.
12. Mielants H, Veys EM, De Vos M, et al. Increased intestinal permeability in ankylosing spondylitis. Gut. 1992;33:1150.
13. Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol. 1995;22:2279-2284.
14. Leirisalo-Repo M, Turunen U, Stenman S, et al. High frequency of silent inflammatory bowel disease in spondyloarthropathy. Arthritis Rheum. 1994;37:23-31.
15. De Keyser F, Baeten D, Van den Bosch F, et al. Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep. 2002;4:525-532.
16. Mielants H, De Keyser F, Baeten D, et al. Gut inflammation in the spondyloarthropathies. Curr Rheumatol Rep. 2005;7:188-194.
17. Orlando A, Renna S, Perricone G, et al. Gastrointestinal lesions associated with spondyloarthropathies. World J Gastroenterol. 2009;15:2443-2448.
18. Ramos PS, Criswell LA, Moser KL, et al. A comprehensive analysis of shared loci between systemic lupus erythematosus (SLE) and sixteen autoimmune diseases reveals limited genetic overlap. PLoS Genet. 2011;7:e1002406.
19. Rosenbaum JT, Lin P, Asquith M, et al. Does the microbiome play a causal role in spondyloarthritis? Clin Rheumatol. 2014;33:763-767.
20. Salmi M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol. 2001;166:4650-4657.
21. Pittet V, Juillerat P, Mottet C, et al. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol. 2009;38:922-931.
22. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16-19.
23. Juillerat P, Pittet V, Bulliard JL, et al. Prevalence of inflammatory bowel disease in the Canton of Vaud (Switzerland): a population-based cohort study. J Crohns Colitis. 2008;2:131-141.
24. Cheung PP, Paternotte S, Burki V, et al. Performance of the Assessment in Spondyloarthritis International Society classification for axial and peripheral spondyloarthritis in an established clinical cohort: comparison with criteria sets of Amor and the European Spondyloarthropathy Study Group. J Rheumatol. 2012;39:816-821.
25. Scarpa R, Biondi Oriente C, Oriente P. The classification of psoriatic arthritis: what will happen in the future? J Am Acad Dermatol. 1997;36: 78-83.
26. Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25-31.
27. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777-783.
28. Rostom S, Dougados M, Gossec L. New tools for diagnosing spondyloarthropathy. Joint Bone Spine. 2010;77:108-114.
29. van den Berg R, de Hooge M, Rudwaleit M, et al. ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. Ann Rheum Dis. 2013;72:1646-1653.
30. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
31. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
32. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330: 1841-1845.
33. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006;55(suppl 1):i1-15.
34. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786.
35. Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am J Gastroenterol. 1988;83:703-709.
36. Rankin GB, Watts HD, Melnyk CS, et al. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology. 1979;77:914-920.
37. Gran JT, Husby G. Joint manifestations in gastrointestinal diseases. 1. Pathophysiological aspects, ulcerative colitis and Crohn's disease. Dig Dis. 1992;10:274-294.
38. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110-119.
39. Grant AJ, Lalor PF, Salmi M, et al. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet. 2002;359:150-157.
40. Harel-Meir M, Sherer Y, Shoenfeld Y. Tobacco smoking and autoimmune rheumatic diseases. Nat Clin Pract Rheumatol. 2007;3:707-715.
41. Albano SA, Santana-Sahagun E, Weisman MH. Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum. 2001;31:146-159.
42. Ciurea A, Finckh A. Smoking and spondyloarthritis. Joint Bone Spine. 2013;80:234-235.
43. Somerville KW, Logan RF, Edmond M, et al. Smoking and Crohn's disease. Br Med J (Clin Res Ed). 1984;289:954-956.
44. Cosnes J. Smoking, physical activity, nutrition and lifestyle: environmental factors and their impact on IBD. Dig Dis. 2010;28:411-417.
45. Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis. 2004;10:848-859.
46. Rom O, Avezov K, Aizenbud D, et al. Cigarette smoking and inflammation revisited. Respir Physiol Neurobiol. 2013;187:5-10.
47. Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohns Colitis. 2014;8:717-725.